<- Go Home
Wave Life Sciences, Inc.
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington’s disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Market Cap
$947.8M
Volume
4.1M
Cash and Equivalents
$368.0M
EBITDA
-$214.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$132.1M
Profit Margin
202.00%
52 Week High
$21.73
52 Week Low
$4.64
Dividend
N/A
Price / Book Value
2.05
Price / Earnings
-4.47
Price / Tangible Book Value
2.05
Enterprise Value
$500.8M
Enterprise Value / EBITDA
-2.45
Operating Income
-$217.9M
Return on Equity
67.42%
Return on Assets
-33.60
Cash and Short Term Investments
$490.6M
Debt
$43.6M
Equity
$453.5M
Revenue
$65.4M
Unlevered FCF
-$128.8M
Sector
Pharmaceuticals
Category
N/A